☆ 4.6 Review

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

FRONTIERS IN ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Endocrinology & Metabolism

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Marcia S. Brose et al.

Summary: This study compared the efficacy and toxicity of lenvatinib starting at doses of 24 mg/day and 18 mg/day in patients with RR-DTC. The results showed that the objective response rate was 57.3% in the 24 mg/day arm and 40.3% in the 18 mg/day arm, indicating that the starting dose of 18 mg/day did not demonstrate noninferiority. However, there was no clinically relevant difference in the safety profile between the two arms.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea

Junhwan Kim et al.

Summary: This study investigated the effectiveness and safety of pembrolizumab and lenvatinib for recurrent endometrial cancer in a real-world setting. The results showed lower treatment response rate and similar treatment discontinuation rate compared to clinical trials.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study

Robert Motzer et al.

Summary: This text is a copyright notice.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer

Marta Di Stefano et al.

Summary: This study evaluated the prevalence of acute cholecystitis in patients with thyroid cancer receiving Lenvatinib treatment. It found that patients developed gallbladder-related symptoms shortly after starting the treatment, highlighting the importance of prompt diagnosis and treatment.

EUROPEAN THYROID JOURNAL (2021)

添加到收藏夹

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer

Jeffrey A. How et al.

Summary: In recurrent endometrial cancer patients, pembrolizumab/lenvatinib combination therapy with a lower starting dose of lenvatinib (14 mg daily) was found to be safe and effective. There were no significant differences in response rates, survival outcomes, and toxicity between the recommended dose group and reduced dose group. However, the recommended dose group required more lenvatinib dose reductions and experienced quicker onset of treatment toxicity.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Valentina Burgio et al.

Summary: This multicentric study in Italy demonstrated that patients with unresectable HCC treated with lenvatinib had lower risk of death, longer progression-free survival, higher response rate compared to those treated with sorafenib. Lenvatinib was also associated with different safety profile than sorafenib in Italian patients.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

N. Colombo et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer

Stefano Fogli et al.

Summary: Lenvatinib is a non-selective tyrosine kinase inhibitor that is most effective in patients with thyroid cancer. The drug is well tolerated and common adverse reactions can be managed by dose adjustment. Monitoring of blood pressure and cardiac function may be required during treatment.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).

Domenica Lorusso et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

Vicky Makker et al.

Summary: The combination of lenvatinib plus pembrolizumab in the treatment of advanced endometrial carcinoma following prior systemic therapy showed efficacy, with manageable safety profile and common adverse reactions occurring within the first 10 weeks of treatment. Most adverse reactions were managed through study drug dose modifications and concomitant medications.

ONCOLOGIST (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer

Viktoria Florentine Koehler et al.

Summary: Sorafenib, lenvatinib, and pazopanib are effective treatment options for the majority of patients with RAI-refractory DTC. Patients treated with lenvatinib and pazopanib in the first-line setting show favorable PFS and six-month survival rates compared to sorafenib.

THYROID (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib

F. Platini et al.

Summary: Late toxicities of lenvatinib in RAI-resistant DTC patients are not negligible, with cardiovascular toxicity being the most common side effect. There were no significant differences in the incidence of late adverse events, lenvatinib treatment duration, and overall survival between older and younger patients.

ENDOCRINE (2021)

添加到收藏夹

Article Oncology

Lenvatinib in Management of Solid Tumors

Zhonglin Hao et al.

ONCOLOGIST (2020)

添加到收藏夹

Review Oncology

Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs

Stefano Fogli et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Article Oncology

Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer

N. Reed et al.

CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Matthew H. Taylor et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo

CANCERS (2020)

添加到收藏夹

Article Oncology

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato et al.

PLOS ONE (2019)

添加到收藏夹

Review Oncology

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

Lorenza Rimassa et al.

CANCER TREATMENT REVIEWS (2019)

添加到收藏夹

Article Oncology

Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer

Yukiko Staub et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy

L. D. Locati et al.

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine- refractory differentiated thyroid cancer

Makoto Tahara et al.

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Review Oncology

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer

Maria E. Cabanillas et al.

SEMINARS IN ONCOLOGY (2019)

添加到收藏夹

Review Peripheral Vascular Disease

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease

Arvind K. Pandey et al.

HYPERTENSION (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Optimal management of patients with hepatocellular carcinoma treated with lenvatinib

Masafumi Ikeda et al.

EXPERT OPINION ON DRUG SAFETY (2018)

添加到收藏夹

Review Oncology

New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome

Leah J. Wilson et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Kenji Ikeda et al.

JOURNAL OF GASTROENTEROLOGY (2017)

添加到收藏夹

Article Oncology

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

Toshiyuki Tamai et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Oncology

Landscape of Microsatellite Instability Across 39 Cancer Types

Russell Bonneville et al.

JCO PRECISION ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Masafumi Ikeda et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Endocrinology & Metabolism

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Bryan R. Haugen et al.

THYROID (2016)

添加到收藏夹

Article Oncology

Cancer-Related Fatigue, Version 2.2015

Ann M. Berger et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Chemistry, Medicinal

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization

Kiyoshi Okamoto et al.

ACS MEDICINAL CHEMISTRY LETTERS (2015)

添加到收藏夹

Article Oncology

VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment

Wouter B. Nagengast et al.

CANCER RESEARCH (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.